3β,11α-dihydroxy-17,20-epoxy-21-nor-5-pregnene | 56103-42-5

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: 3β,11α-dihydroxy-17,20-epoxy-21-nor-5-pregnene
• 英文别名: (3S,8S,9S,10R,11R,13S,14S,17R)-10,13-dimethylspiro[1,2,3,4,7,8,9,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthrene-17,2'-oxirane]-3,11-diol
• CAS: 56103-42-5
• 化学式: C₂₀H₃₀O₃
• 分子量: 318.456
• InChiKey: HRNVBOYCWMORFT-WSIJOFGPSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  23
• 可旋转键数：
  0
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.9
• 拓扑面积：
  53
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  11α-hydroxy-dehydroepiandrosterone 以 N-甲基乙酰胺 为溶剂， 生成 3β,11α-dihydroxy-17,20-epoxy-21-nor-5-pregnene
  参考文献：
  名称：

  D-homosteroids

  摘要：

  公开了化学式为##STR1##的新型D-同系甾体。这种新型D-同系甾体具有抗炎活性，并可用作合成抗炎D-同系甾体的中间体。

  公开号：

  US04026918A1

文献信息

• NEUROSTEROID COMPOUNDS
  申请人：Gravanis Achilleas

  公开号：US20100234335A1

  公开（公告）日：2010-09-16

  The present invention relates to novel neurosteroid derivatives with anti-apoptotic, neuroprotective and neurogenic properties that act on the nervous system as well as methods for making the same and their applications in the treatment and/or prevention or amelioration of neurodegenerative diseases related to neuronal apoptosis or neuronal injury, or conditions related to or resulting from apoptosis, including but not limited to Alzheimer's disease, Parkinson's disease, Huntington's disease, multiple sclerosis and amyotrophic lateral sclerosis (ALS), retinal degeneration and detachment, peripheral neuropathy caused by genetic abnormalities, diabetes, polio, herpes, AIDS and chemotherapy, brain trauma, or ischemia and stroke. The active compounds are represented by Formula (I): wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , A, B, X, Y and Z are defined in the description of the invention. The present invention also includes compositions which comprise one or more of the compounds of Formula (I).

  本发明涉及具有抗凋亡、神经保护和神经生成特性的新型神经类固醇衍生物，其作用于神经系统，以及制备这些衍生物的方法以及它们在治疗和/或预防或改善与神经元凋亡或神经元损伤相关的神经退行性疾病或与凋亡相关或由凋亡导致的疾病，包括但不限于阿尔茨海默病、帕金森病、亨廷顿病、多发性硬化症和肌萎缩侧索硬化症（ALS）、视网膜变性和脱离、由遗传异常引起的周围神经病变、糖尿病、小儿麻痹症、疱疹、艾滋病和化疗、脑外伤、缺血和中风。活性化合物由式（I）表示：其中R1、R2、R3、R4、R5、R6、R7、A、B、X、Y和Z在本发明描述中有定义。本发明还包括包含式（I）中的一个或多个化合物的组合物。
• USE OF STEROID COMPOUNDS
  申请人：Panoutsakopoulou Vasiliki

  公开号：US20120225852A1

  公开（公告）日：2012-09-06

  This invention pertains to the use of steroid compounds including spirosteroid analogues in treating, preventing or ameliorating the symptoms of inflammatory conditions. The steroid compounds are useful for treating a range of inflammatory conditions, including, but not limited to asthma, lung inflammation, retinal inflammatory conditions, autoimmune diseases such as rheumatoid arthritis, diabetes type I, systemic lupus erythematosus, ulcerative colitis and inflammatory bowel diseases and myopathies, as well as multiple sclerosis. The active compounds are represented by Formula I: wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , A, B, X, Y and Z are defined in the description of the invention.
• US4026918A
  申请人：——

  公开号：US4026918A

  公开（公告）日：1977-05-31
• US4026921A
  申请人：——

  公开号：US4026921A

  公开（公告）日：1977-05-31
• US9777037B2
  申请人：——

  公开号：US9777037B2

  公开（公告）日：2017-10-03